Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3

Ren,Jianbo; Xu,Gang; Sun,Hongyan; Lin,Ting; Xu,Sanhui; Zhao,Yating

doi:10.3892/etm.2021.10480

Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3

Authors:
- Jianbo Ren
- Gang Xu
- Hongyan Sun
- Ting Lin
- Sanhui Xu
- Yating Zhao
View Affiliations

Affiliations: Department of Oncology, Yantai Muping Hospital of Traditional Chinese Medicine, Yantai, Shandong 264100, P.R. China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Endoscopy Center, Yantai Muping Hospital of Traditional Chinese Medicine, Yantai, Shandong 264100, P.R. China, Department of Breast Surgery, Tangshan People's Hospital, Lunan, Tangshan, Hebei 063000, P.R. China, 1st Laboratory Department, Xingtai People's Hospital, Xingtai, Hebei 054000, P.R. China, Breast Health Department, Tangshan Maternal Child Health Care Hospital, Tangshan, Hebei 063000, P.R. China
Published online on: July 22, 2021 https://doi.org/10.3892/etm.2021.10480
Article Number: 1047
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRs) have been indicated to serve oncogenic or tumor suppressor roles. However, the role of miR‑483‑5p in breast cancer and its associated molecular mechanisms remain unclear. In the present study, compared with adjacent normal tissues and MCF‑10a cells, the expression level of miR‑483‑5p was upregulated in triple‑negative breast cancer (TNBC) tissues and TNBC cell lines. Bioinformatic analysis and luciferase reporter assay confirmed the presence of miR‑483‑5p binding sites in the 3'‑untranslated region of suppressor of cytokine signaling 3 (SOCS3). In addition, the expression level of SOCS3 protein in TNBC tissues was markedly lower compared with in adjacent tissues, and miR‑483‑5p expression was negatively correlated with SOCS3 expression in TNBC tissues. Cell proliferation and flow cytometry assays indicated that knockdown of miR‑483‑5p inhibited the proliferation and promoted apoptosis in the TNBC cell line BT‑549. This effect was markedly attenuated by SOCS3 small interfering (si)RNA transfection. Additionally, wound healing and Transwell assays demonstrated that SOCS3 siRNA reversed the inhibitory effects of miR‑483‑5p inhibitor on the migration and invasion of BT‑549 cells. Moreover, the decrease in miR‑483‑5p expression significantly reduced the secretion of TNF‑α, IL‑6, IL‑1β and monocyte chemoattractant protein‑1 in BT‑549 cells, while SOCS3 siRNA could partially reverse this effect. Additionally, SOCS3 overexpression reversed the effects of miR‑483‑5p mimic on the proliferation, migration, invasion and inflammation of BT‑549 cells. Taken together, these data demonstrated that the inhibition of miR‑483‑5p could inhibit the proliferation, migration, invasion and inflammatory response, while promoting the apoptosis of TNBC cells by negatively regulating SOCS3. miR‑483‑5p may be a potential target for TNBC therapy.

View Figures

View References

1	Domínguez F, Maycotte P, Acosta-Casique A, Rodríguez-Rodríguez S, Moreno DA, Ferreres F, Flores-Alonso JC, Delgado-López MG, Pérez-Santos M and Anaya-Ruiz Μ: Bursera copallifera Extracts have cytotoxic and migration-inhibitory effects in breast cancer cell lines. Integr Cancer Ther. 17:654–664. 2018.PubMed/NCBI View Article : Google Scholar
2	Geenen JJJ, Linn SC, Beijnen JH and Schellens JH: PARP inhibitors in the treatment of triple-negative breast cancer. Clin Pharmacokinet. 57:427–437. 2018.PubMed/NCBI View Article : Google Scholar
3	Liu J, Shi Z, Bai Y, Liu L and Cheng K: Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer. Cancer Manag Res. 11:4471–4480. 2019.PubMed/NCBI View Article : Google Scholar
4	Paul S, Reyes PR, Garza BS and Sharma A: MicroRNAs and child neuropsychiatric disorders: A Brief Review. Neurochem Res. 45:232–40. 2020.PubMed/NCBI View Article : Google Scholar
5	Dai W, Lu H, Yang F, Dong H and Zhang X: Accurate detection of intracellular microRNAs using functional Mo2C quantum dots nanoprobe. Chem Commun (Camb). 55:10615–10618. 2019.PubMed/NCBI View Article : Google Scholar
6	Li H, He C, Wang X, Wang H, Nan G and Fang L: MicroRNA-183 affects the development of gastric cancer by regulating autophagy via MALAT1-miR-183-SIRT1 axis and PI3K/AKT/mTOR signals. Artif Cells Nanomed Biotechnol. 47:3163–3171. 2019.PubMed/NCBI View Article : Google Scholar
7	Lou Q, Liu R, Yang X, Li W, Huang L, Wei L, Tan H, Xiang N, Chan K, Chen J, et al: miR-448 targets IDO1 and regulates CD8⁺ T cell response in human colon cancer. J Immunother Cancer. 7(210)2019.PubMed/NCBI View Article : Google Scholar
8	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007.PubMed/NCBI View Article : Google Scholar
9	Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R, Mehta S, et al: Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest. 129:5518–5536. 2019.PubMed/NCBI View Article : Google Scholar
10	Li H, Bian C, Liao L, Li J and Zhao RC: miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat. 126:565–575. 2011.PubMed/NCBI View Article : Google Scholar
11	Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000.PubMed/NCBI View Article : Google Scholar
12	Gao Y, Zhang W, Liu C and Li G: miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB. Sci Rep. 9(18844)2019.PubMed/NCBI View Article : Google Scholar
13	Girardot M, Cavaillé J and Feil R: Small regulatory RNAs controlled by genomic imprinting and their contribution to human disease. Epigenetics. 7:1341–1348. 2012.PubMed/NCBI View Article : Google Scholar
14	Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, et al: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692. 2009.PubMed/NCBI View Article : Google Scholar
15	Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, Zhang Y, Lai P, Fan X, Zhou X, et al: miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 74:3031–3042. 2014.PubMed/NCBI View Article : Google Scholar
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
17	Meirson T and Gil-Henn H: Targeting invadopodia for blocking breast cancer metastasis. Drug Resist Updat. 39:1–17. 2018.PubMed/NCBI View Article : Google Scholar
18	De Sanctis V, Agolli L, Visco V, Monaco F, Muni R, Spagnoli A, Campanella B, Valeriani M, Minniti G, Osti MF, et al: Cytokines, fatigue, and cutaneous erythema in early stage breast cancer patients receiving adjuvant radiation therapy. Biomed Res Int. 2014(523568)2014.PubMed/NCBI View Article : Google Scholar
19	Zhang H, Shi X, Chang W, Li Y and Wang L and Wang L: Epigenetic alterations of the Igf2 promoter and the effect of miR 483 5p on its target gene expression in esophageal squamous cell carcinoma. Mol Med Rep. 17:2251–2256. 2018.PubMed/NCBI View Article : Google Scholar
20	Wang L, Shi M, Hou S, Ding B, Liu L, Ji X, Zhang J and Deng Y: MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett. 586:1312–1317. 2012.PubMed/NCBI View Article : Google Scholar
21	Lemberger M, Loewenstein S, Lubezky N, Nizri E, Pasmanik-Chor M, Barazovsky E, Klausner JM and Lahat G: MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. Oncotarget. 10:2644–2656. 2019.PubMed/NCBI View Article : Google Scholar
22	Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, et al: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 8(R214)2007.PubMed/NCBI View Article : Google Scholar
23	Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Cristian Lolli C, Kinspergher S, Schepisi G, et al: Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol. 36:240.e1–.e11. 2018.PubMed/NCBI View Article : Google Scholar
24	Garbers C and Rose-John S: Dissecting interleukin-6 classic-and trans-signaling in inflammation and cancer. Methods Mol Biol. 1725:127–140. 2018.PubMed/NCBI View Article : Google Scholar
25	Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, et al: SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene. 34:671–680. 2015.PubMed/NCBI View Article : Google Scholar
26	Klepsch O, Namer LS, Köhler N, Kaempfer R, Dittrich A and Schaper F: Intragenic regulation of SOCS3 isoforms. Cell Commun Signal. 17(70)2019.PubMed/NCBI View Article : Google Scholar
27	Li H, Zhang B, Ding M, Lu S, Zhou H, Sun D, Wu G and Gan X: C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3. Hepatol Int. 13:277–292. 2019.PubMed/NCBI View Article : Google Scholar
28	Singh S, Chouhan S, Mohammad N and Bhat MK: Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3. FEBS Lett. 591:1371–1382. 2017.PubMed/NCBI View Article : Google Scholar
29	Li MZ, Lai DH, Zhao HB, Chen Z, Huang QX and Situ J: SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells. Eur Rev Med Pharmacol Sci. 21:3005–3011. 2017.PubMed/NCBI
30	Muhammad N, Bhattacharya S, Steele R and Ray RB: Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 7:58595–58605. 2016.PubMed/NCBI View Article : Google Scholar
31	Christopher AF, Gupta M and Bansal P: Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. Gene. 594:30–40. 2016.PubMed/NCBI View Article : Google Scholar
32	Zakaria N, Mohd Yusoff N, Zakaria Z, Widera D and Yahaya BH: Inhibition of NF-κB signaling reduces the stemness characteristics of lung ccancer stem cells. Front Oncol. 8(166)2018.PubMed/NCBI View Article : Google Scholar
33	Zhang X, Wan Q and Xu TS: Effect of Grain-moxibustion on IL-6 and STAT 3 in inflammatory microenvironment of Lewis lung cancer mice. Zhen Ci Yan Jiu. 42:235–239. 2017.PubMed/NCBI(In Chinese).
34	Chen L, Heikkinen L, Wang C, Yang Y, Sun H and Wong G: Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 20:1836–1852. 2019.PubMed/NCBI View Article : Google Scholar